Company Profile
In January 2011, Boehringer Ingelheim and Eli Lilly and Company announced an alliance that centres on compounds representing several of the largest diabetes treatment classes. Depending on geographies, the companies either co-promote or separately promote the respective molecules each contributing to the alliance. The Alliance leverages the strengths of two of the world’s leading pharmaceutical companies to focus on patient needs. By joining forces, the companies demonstrate their commitment, not only to the care of people with diabetes, but also to investigating the potential to address areas of unmet medical need
The Boehringer Ingelheim and Lilly Diabetes Alliance has provided the funding for this promotional meeting, including speaker honoraria and presentation support where applicable
Click here for prescribing Information and adverse event reporting (UK) JARDIANCE (empagliflozin)
Click here for prescribing information and adverse event reporting (IE) JARDIANCE (empagliflozin)
The multiple effects of SGLT2 inhibitors on the Cardio–Renal–Metabolic system in type 2 diabetes
This promotional video presentation was originally broadcast on 6 November 2020. Please note that the speakers are not able to answer questions from attendees watching the video on-demand.
Resources
Improving cardiovascular outcomes in type 2 diabetes with SGLT2 inhibitors – What is the role of the cardiologist? videos.
PC-GB-103149 | Date of prep: November 2020
